Superhouse Annual Report FY25: Standalone PAT up 69% on better margins

Pat Growth 25pctEbitda Margin ExpansionRevenue DeclineExceptional ItemResults View source PDF Explain this filing

SUPERHOUSE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹164.10

prior close

₹167.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+0.4% vs market

Leather And Leather Products peers, median of 11sector+0.1%+0.6% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 0.6 pts more than its Leather And Leather Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

+0.0

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+0.3+0.4+0.1+0.6

Next day

+3.0+0.5+2.5+0.9+2.1

+7.8+0.1+7.8+1.9+5.9

+7.3+0.7+6.6+3.1+4.2

+3.9+0.4+3.5+2.2+1.7

+7.2+0.7+6.5+2.7+4.5

+3.9+0.1+3.8+1.2+2.7

15d

+3.1+1.5+1.7-0.7+3.8

+2.7+0.3+2.4+0.6+2.1

-7.6-6.2-1.4+3.9-11.4

—————

UpDownMarket · Nifty Microcap 250Sector · Leather And Leather Products peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Superhouse Limited filed its FY2024-25 Annual Report ahead of the 45th AGM on Sep 30, 2025. Standalone revenue fell 3% to Rs. 504.91 crore but PAT jumped 69% to Rs. 13.41 crore on 26% EBIDTA growth. EPS rose to Rs. 12.17 from Rs. 7.19. Consolidated PAT fell to Rs. 7.66 crore from Rs. 11.73 crore. Exceptional items of Rs. 6.20 crore boosted profits. Dividend held at Rs. 0.80 per share. Credit rating outlook revised to Negative from Stable.

Likely market impact

Strong standalone earnings recovery on margins despite revenue dip. Negative credit outlook and weaker consolidated PAT remain concerns. Dividend maintained.